Alkermes (ALKS) Cash & Equivalents Growth (1y) (2011 - 2026)
Alkermes (ALKS) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | -4.65% |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -1.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.86% |
| Mar 31, 2026 | -12.07% |
| Dec 31, 2025 | 33.46% |
| Sep 30, 2025 | 55.55% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | -4.98% |
| Dec 31, 2024 | -36.36% |
| Sep 30, 2024 | -38.82% |
| Jun 30, 2024 | -19.62% |
| Mar 31, 2024 | 30.91% |
| Dec 31, 2023 | 56.41% |
| Sep 30, 2023 | 145.39% |
| Jun 30, 2023 | 161.46% |
| Mar 31, 2023 | 13.75% |
| Dec 31, 2022 | -13.35% |
| Sep 30, 2022 | -14.97% |
| Jun 30, 2022 | -1.43% |
| Mar 31, 2022 | 37.81% |
| Dec 31, 2021 | 23.66% |
| Sep 30, 2021 | 28.89% |